Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment

COVID-19 vaccines: where we stand and challenges ahead

(2021) Guido Forni et al.   CELL DEATH AND DIFFERENTIATION

The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate

(2021) M.C. Garassino et al.   ANNALS OF ONCOLOGY

COVID-19 vaccination: the VOICE for patients with cancer

(2021) Astrid A. M. van der Veldt et al.   NATURE MEDICINE

Recommendations and Guidance for Steroid Injection Therapy and COVID-19 Vaccine Administration from the American Society of Pain and Neuroscience (ASPN)

(2021) Krishnan Chakravarthy et al.   Journal of Pain Research

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

(2021) R. Palich et al.   ANNALS OF ONCOLOGY

Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors

(2021) J. Barrière et al.   ANNALS OF ONCOLOGY

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

(2021) Barliz Waissengrin et al.   LANCET ONCOLOGY

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

(2021) Leticia Monin et al.   LANCET ONCOLOGY

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

(2021) Aakash Desai et al.   Nature Reviews Clinical Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

(2021) Astha Thakkar et al.   CANCER CELL

Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer

(2021) Jérôme Barrière et al.   EUROPEAN JOURNAL OF CANCER

Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data

(2021) Luigi Cari et al.   JOURNAL OF AUTOIMMUNITY

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

(2021) Evangelos Terpos et al.   Journal of Hematology & Oncology

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

(2021) Dami A. Collier et al.   NATURE

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

(2020) Nicole M Kuderer et al.   LANCET

Estradiol, progesterone, immunomodulation and COVID-19 outcomes

(2020) Franck Mauvais-Jarvis et al.   ENDOCRINOLOGY

Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis

(2020) Qianwen Zhao et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Clinical And Analytical Performance Of An Automated Serological Test That Identifies S1/S2 Neutralizing IgG In COVID-19 Patients Semiquantitatively.

(2020) Fabrizio Bonelli et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

(2020) Mark Ainsworth et al.   LANCET INFECTIOUS DISEASES

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

(2020) Lennard Y W Lee et al.   LANCET ONCOLOGY

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

What’s Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses

(2020) Nirupa Gadi et al.   Frontiers in Immunology

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impacts of cigarette smoking on immune responsiveness: Up and down or upside down?

(2016) Feifei Qiu et al.   Oncotarget